Schering-Plough and PTC Therapeutics Announce Collaboration for Development of PTC's Preclinical Hepatitis C (Hepatitis C Infection) Compounds

Schering-Plough and PTC Therapeutics Announce Collaboration for Development of PTC's Preclinical Hepatitis C Compounds
[Press Release] PR Newswire via Yahoo! Finance - Mar 20 5:30 AM
Schering-Plough Corporation and PTC Therapeutics, Inc. today announced that they have entered into an exclusive collaboration and licensing agreement for the development of PTC's preclinical compounds for the oral treatment of hepatitis C virus infection and other viral diseases.Save to My Web

Coley Pharmaceutical Group Announces Top-line Data from a Clinical Study of Actilon(TM) for Hepatitis C
[Press Release] PR Newswire via Yahoo! Finance - Mar 21 5:30 AM
Coley Pharmaceutical Group, Inc. today announced positive top-line interim data from the company's twelve-week, randomized, controlled clinical study of Actilon in combinations with pegylated interferon and/or ribavirin for the treatment of chronic Hepatitis C virus in the relapsed subset of treatment experienced patients.Save to My Web

Novelos Therapeutics files IND for new hepatitis C drug
BizJournals - Mar 22 8:23 AM
Novelos Therapeutics Inc., a Newton-based biotechnology company focused on the development of therapeutics to treat cancer and hepatitis, has filed an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration for NOV-205, its second clinical stage compound.Save to My Web

euro adhoc: Intercell AG / Financial Figures/Balance Sheet / Intercell announces preliminary 2005 full year
vwd.de - Mar 05 10:43 PM
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement.Save to My Web

Novelos Therapeutics Announces $15 Million Private Placement, Supplementing Today's Earlier Announcement
[Press Release] Business Wire via Yahoo! Finance - Mar 02 4:12 PM
NEWTON, Mass.----March 2, 2006--Novelos Therapeutics, Inc. , a biotechnology company focused on the development of therapeutics to treat cancer and hepatitis, today announced that it has entered into definitive securities purchase agreements with institutional investors to raise $15.06 million in gross proceeds through the sale of shares of its common stock and warrants.Save to My Web